Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Mainz Biomed B.V. ( (MYNZ) ) has issued an update.
On March 11, 2026, Mainz Biomed appointed cybersecurity and quantum computing veteran Robert P. Liscouski as chairman of its board of directors, with his permanent election expected to be confirmed at an extraordinary general meeting planned for April 2026. The move installs a high-profile technology and security figure with deep U.S. government and corporate experience as the company pivots its strategy and leadership.
Also on March 11, 2026, the company said it will begin doing business as Quantum Cyber and will switch its Nasdaq ticker from MYNZ to QUCY effective before the market opens on March 12, 2026, without changing existing shareholder rights or its CUSIP. The rebranding, combined with board changes and the ongoing shift toward pancreatic cancer screening and asset divestitures, signals a broad strategic repositioning aimed at aligning the business more closely with advanced technology and cybersecurity themes.
The most recent analyst rating on (MYNZ) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Mainz Biomed B.V. stock, see the MYNZ Stock Forecast page.
Spark’s Take on MYNZ Stock
According to Spark, TipRanks’ AI Analyst, MYNZ is a Neutral.
The score is primarily constrained by weak financial performance, including persistent losses, negative operating cash flow, and high leverage. Technicals offer only modest support with short-term improvement but a longer-term downtrend. Valuation impact is neutral due to missing P/E and dividend yield data.
To see Spark’s full report on MYNZ stock, click here.
More about Mainz Biomed B.V.
Mainz Biomed N.V., soon to operate under the name Quantum Cyber, is a molecular genetics diagnostics company focused on the early detection of cancer. The business has been concentrating on developing a U.S.-based pancreatic cancer screening franchise while exploring the sale of its colorectal cancer screening assets and winding down its German subsidiary.
Average Trading Volume: 488,378
Technical Sentiment Signal: Sell
Current Market Cap: $7.49M
Learn more about MYNZ stock on TipRanks’ Stock Analysis page.